Company: BOLT
Filing Date: 2025-03-24
Form Type: 10-K
Source: 0000950170-25-043873
Chunk: 153

Company: Bolt Biotherapeutics, Inc.
Filing Date: 2025-03-24
Form: 10-K
Item: Item 1B
Chunk 153
---
456

    Operating lease liabilities, net of current portion

    22,958

    17,437

    Deferred revenue, non-current

    3,620

    9,107

    Other long-term liabilities

    —

    43

    Total liabilities

    42,434

    47,043

    Commitments and contingencies (Note 7)

    Stockholders' equity:

    Common stock, $0.00001 par value; 200,000,000 shares authorized at December 31, 2024 and 2023; 38,339,697 and 38,114,606 shares issued and outstanding at December 31, 2024 and 2023, respectively

    —

    —

    Additional paid-in capital

    484,504

    476,989

    Accumulated other comprehensive gain

    97

    37

    Accumulated deficit

    (427,403
    )

    (364,285
    )

    Total stockholders' equity

    57,198

    112,741

    Total liabilities and stockholders' equity
     
    $
    99,632

    $
    159,784

See accompanying notes to the consolidated financial statements.

89

BOLT BIOTHERAPEUTICS, INC. 

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS 

(in thousands, except share and per share amounts) 

    Years Ended December 31,

    2024

    2023

    Collaboration revenue
     
    $
    7,690

    $
    7,876

    Operating expenses:

    Research and development

    57,469

    61,542

    General and administrative

    18,457

    22,530

    Restructuring charges

    3,343

    —

    Impairment charges

    1,469

    —

    Total operating expense

    80,738

    84,072

    Loss from operations

    (73,048
    )

    (76,196
    )

    Other income (expense), net:

    Interest income, net

    5,255

    6,999

    Other income, net

    4,675

    —

    Total other income, net

    9,930

    6,999